Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used to advance the clinical development of AP31969, an SK ion channel inhibitor optimised for chronic oral treatment of atrial fibrillation.
Lead Product(s): AP31969
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AP31969
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Canaan
Deal Size: $47.6 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 26, 2023
Details:
AP31969 is the second-generation oral SK ion channel inhibitor, which is being developed for chronic oral maintenance treatment to prevent AF recurrence.
Lead Product(s): AP31969
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AP31969
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
AP30663 is a first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm. It is being developed for the treatment of atrial fibrillation.
Lead Product(s): AP30663
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AP30663
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023